Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing

Issued Date

2022-07-01

Resource Type

Article

ISSN

07368046

eISSN

15251470

DOI

10.1111/pde.15074

Scopus ID

2-s2.0-85136479357

Pubmed ID

36000937

Journal Title

Pediatric Dermatology

Volume

39

Issue

4

Start Page

601

End Page

605

Rights Holder(s)

SCOPUS

Bibliographic Citation

Pediatric Dermatology Vol.39 No.4 (2022) , 601-605

Suggested Citation

Siripipattanamongkol N., Rattanasak S., Taiyaitieng C., Inthajak Y., Kuawatcharawong N., Sukasem C., Tempark T. Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing. Pediatric Dermatology Vol.39 No.4 (2022) , 601-605. 605. doi:10.1111/pde.15074 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87280

Title

Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing

Author(s)

Siripipattanamongkol N.
 Rattanasak S.
 Taiyaitieng C.
 Inthajak Y.
 Kuawatcharawong N.
 Sukasem C.
 Tempark T.

Author's Affiliation

University of Liverpool
 Bumrungrad International Hospital
 Faculty of Medicine Ramathibodi Hospital, Mahidol University
 Faculty of Medicine, Chulalongkorn University
 Chiangrai Prachanukroh Hospital

Other Contributor(s)

Mahidol University

Abstract

Toxic epidermal necrolysis (TEN) is a rare and acute life-threatening condition and one of the severe cutaneous adverse drug reactions. There are limited data on TEN from the COVID-19 vaccine regarding its pathogenesis, treatment, and prognosis, particularly in children. We report a case of COVID-19 vaccine-induced TEN and the patient's human leukocyte antigen pharmacogenomic profile.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/87280

Collections

Scopus 2022